Table 2

COVID-19 associated biochemical markers, LS and clinical course

No liver damage
(LS <5 kPa) n=20
Liver damage
(LS >5 kPa) n=12
P value
Spleen size (cm)10.8 (±2.1)11.1 (±1.9)0.44
Liver stiffness (kPA)3.4 (±1.2)7.8 (±1.8)0.001*
IQR/M liver0.5 (±0.3)1.5 (±0.4)n.a.
CAP (dB/m)213.1 (±61.5)212.2 (±80.4)0.70
Spleen stiffness (kPA)28.1 (±19.8)30.4 (±10.7)0.78
IQR/M spleen0.6 (±0.2)8.6 (±3.7)n.a.
Bilirubin (mg/dL)0.43 (±0.22)0.42 (±0.2)0.43
AST (U/L) 19.5 (±5.3) 67.1 (±31.5) 0.001*
ALT (U/L) 31.3 (±8.3) 76.3 (30.6) 0.001*
GGT (U/L) 31.3 (±14.3) 92.3 (±51.4) 0.001*
Alkaline phosphatase (U/L)255.6 (±59.6)306.4 (±112.5)0.12
Creatine kinase (U/L)118.6 (±58.7)96.5 (±42.9)0.73
Troponin T (ng/L)18.2 (±13.2)12.1 (±4.2)0.62
Creatinine (mg/dL)0.9 (±0.3)0.9 (±0.3)˃0.99
BMI (kg/m2)24.1 (±3.2)24.7 (±2.7)0.58
Max. AST (U/L) 49.6 (±21.3) 83.7 (±27.2) 0.001*
Max. ALT (U/L) 46.6 (±13.6) 72.5 (±26.2) 0.001*
SBP (mm Hg)*115.7 (±7.6)115.1 (±11.1)0.99
MBP (mm Hg)*91.6 (±7.4)92 (±9.2)0.58
DBP (mm Hg)*67.5 (±9.5)68.3 (±13.4)0.67
LDH (U/L)72.5 (±33.5)79.9 (±28.8)0.54
CRP (mg/dL)5.7 (±4.5)5.1 (±3.0)0.70
Leucocytes (g/L)5.0 (±2.1)5.9 (±3.9)0.41
Haemoglobin (g/L)127.3 (±15.3)125.1 (±15.9)0.70
Platelet count (103/µL)226.1 (±89.4)233.7 (±87.5)0.82
Quick %96.1 (±10.2)101,8 (±14.8)0.23
Ferritin (µg/L) 409.1 (±357.8) 1019.8 (±761.2) 0.05*
Onset of symptoms before admission to hospital (days)2.4 (±1.3)2.8 (±1.7)0.61
Length of stay (days) 8 (±1.4) 15 (±7) 0.001*
Admission to ICU 0% 25% 0.007*
Mortality 0% 17% 0.001*
  • bold indicates statistical significant.

  • *SBP, MBP and DBP are given as mean±SD during hospital stay.

  • ALT, alanine transferase; AST, alanine transferase; BMI, body mass index; CAP, controlled attenuation parameter; CRP, C reactive protein; DBP, diastolic blood pressure; GGT, gamma glutamyl transferase; IQR/M, IQR/median value; LS, liver stiffness; MBP, mean blood pressure; SBP, systolic blood pressure.